Table 2.
Prevalence of sarcopenia in different definitions and its association with outcomes
| Definition of sarcopenia and muscle mass assessment | Discovery cohort (n=492) | External test set (n=161) | External LT test set (n=173) | |||||
|---|---|---|---|---|---|---|---|---|
| n (%) |
RFS (HR, 95% CI) |
OS (HR, 95% CI) |
n (%) |
OS (HR, 95% CI) |
n (%) |
RFS (HR, 95% CI) |
OS (HR, 95% CI) |
|
| Golse et al. (2017)M: PMA<1561 mm2F: PMA<1464 mm2 | 216 (43.9%) | 1.04 (0.80‒1.35)P=0.76 | 1.58 (1.07‒2.35)P=0.02 |
54 (33.5%) |
1.58 (0.81‒3.06) P=0.18 |
71 (41.0%) | 1.24 (0.64‒2.38)P=0.52 | 1.59 (0.76‒3.31)P=0.22 |
| Hamaguchi et al. (2016)M: PMI<6.36 cm2/m2F: PMI<3.92 cm2/m2 | 263 (53.5%) | 1.14 (0.88‒1.48)P=0.31 | 1.57 (1.05‒2.35)P=0.03 |
81 (50.3%) |
1.27 (0.66‒2.45) P=0.48 |
100 (57.8%) | 1.37 (0.70‒2.65)P=0.36 | 1.47 (0.70‒3.13)P=0.31 |
|
Yoo et al. (2017) PD<38.5 HU |
20 (4.1%) | 1.27 (0.68‒2.40)P=0.45 | 2.11 (0.92‒4.85)P=0.08 | 0 | NA | 5 (2.9%) | 5.98 (1.33‒26.90)P=0.02 | 5.47 (1.25‒23.92)P=0.02 |
| Carey et al. (2017)M: SMI≤50 cm2/m2F: SMI≤39 cm2/m2 | 290 (58.9%) | 1.10 (0.84‒1.43)P=0.49 | 1.52 (1.00‒2.31)P=0.05 |
97 (60.2%) |
1.92 (0.92‒3.98) P=0.08 |
87 (50.3%) | 1.08 (0.55‒2.11)P=0.83 | 1.23 (0.57‒2.66)P=0.60 |
| Fujiwara et al. (2015)M: MA≤44.4 HUF: MA≤39.3 HU | 352 (71.5%) | 1.31 (0.97‒1.76)P=0.07 | 1.52 (0.96‒2.40)P=0.08 |
8 (5.0%) |
0.52 (0.07‒3.82) P=0.52 |
136 (78.6%) | 1.34 (0.61‒2.95)P=0.47 | 2.44 (0.84‒7.05)P=0.10 |
LT, liver transplantation; RFS, recurrence-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; M: male; F: female; PMA, psoas muscle area; PMI, psoas muscle index; PD, psoas muscle density; SMI, skeletal muscle index; MA, mean muscle attenuation; HU, Hounsfield unit; NA, not available.